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Primary effusion lymphomaInfection with HIV ultimately leads to advanced immunodeficiency resulting in an increased incidence of cancer.
For example primary effusion lymphoma (PEL) is an aggressive non-Hodgkin lymphomawith very poor progno-
sis that typically affects HIV infected individuals in advanced stages of immunodeficiency. Here we report on the
dual anti-HIV and anti-PEL effect of targeting a single process common in both diseases. Inhibition of the
exportin-1 (XPO1) mediated nuclear transport by clinical stage orally bioavailable small molecule inhibitors
(SINE) prevented the nuclear export of the late intron-containing HIV RNA species and consequently potently
suppressed viral replication. In contrast, in CRISPR-Cas9 genome edited cells expressing mutant C528S XPO1,
viral replication was unaffected upon treatment, clearly demonstrating the anti-XPO1 mechanism of action. At
the same time, SINE caused the nuclear accumulation of p53 tumor suppressor protein as well as inhibition of
NF-κB activity in PEL cells resulting in cell cycle arrest and effective apoptosis induction. In vivo, oral administra-
tion arrested PEL tumor growth in engraftedmice. Our findings provide strong rationale for inhibitingXPO1 as an
innovative strategy for the combined anti-retroviral and anti-neoplastic treatment of HIV and PEL and offer per-
spectives for the treatment of other AIDS-associated cancers and potentially other virus-related malignancies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The immune systemof individuals infectedwith human immunode-
ficiency virus (HIV) is gradually compromised andwhen untreated ulti-
mately leads to advanced acquired immunodeficiency syndrome
(AIDS), making patients vulnerable to opportunistic infections, malig-
nancies, and other pathologies. Several different types of cancer are ob-
served at an increased incidence in HIV-infected persons compared to
the general population (Boshoff and Weiss, 2002; Cesarman, 2013).
For example, primary effusion lymphoma (PEL) is a very aggressive
non-Hodgkin Lymphoma (NHL) that most regularly appears in patients
with major immunodeficiency, primarily in the context of HIV infection
and advanced stages of AIDS. PEL is by definition associated with
Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8) and most
HIV-positive cases also show evidence of Epstein–Barr virus (EBV)Chemotherapy, Department of
edical Research, KU Leuven,
Daelemans).
. This is an open access article underinfection (Cesarman, 2014). It originates within major body cavities
such as the pleural, peritoneal spaces, or the pericardium. PEL has very
poor prognosiswith a survival timeof two to threemonths after diagno-
sis without treatment and only six months with aggressive chemother-
apy (Chen et al., 2007). There is no standard therapy for the treatment of
PEL and combination chemotherapy is considered first-line therapy
(Chen et al., 2007; Kaplan, 2013). The use of anti-HIV drugs is associated
with better prognosis suggesting antiretroviral therapy as part of the
supportive treatment (Lim et al., 2005a; Boulanger et al., 2005). Other
approaches outside traditional chemotherapy have been investigated,
including the addition of anti-herpes therapy such as cidofovir
(Halfdanarson et al., 2006) or the use of NF-κB inhibitors (Keller et al.,
2006; An et al., 2004). Very recently, brentuximab vedotin (Bhatt
et al., 2013a), which is an anti-CD30 monoclonal antibody conjugated
to the microtubule-disrupting agent monomethyl auristatin E, and a
proteasome-HDAC inhibitor combination (Bhatt et al., 2013b) have
been demonstrated to be effective against PEL. Although patients dis-
play response to therapy, remissions are often short-term and current
chemotherapy approaches still result in poor outcome (Kaplan, 2012,
2013) warranting investigation of original therapeutic strategies for
PEL.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cesses, and one such cellular co-factor is XPO1. In fact, the HIV protein
Rev was first characterized as the prototype cargo protein substrate
for XPO1. Rev highjacks the XPO1-mediated nuclear export pathway
to transport the late viral RNA species to the cytoplasm (Malim et al.,
1989b; Felber et al., 1989; Pollard and Malim, 1998). These late RNA
species are produced by alternative splicing from a single, full-length
proviral transcript and still contain introns. Importantly, effective
replication requires the nuclear export and translation of these intron-
containing RNAs. Under normal circumstances, intron-containing pre-
RNAs are retained in the nucleus by the interaction of splicing factors
until they are either spliced to completion or degraded. In order to
overcome the nuclear retention of intron-containing RNAs by host cell
factors, the early viral gene product Rev forms a multimeric complex
on a secondary structured RNA element (the Rev response element,
RRE) present in all unspliced and partially spliced viral mRNAs. Hence
prior to the onset of splicing, Rev directs their transport to the
cytoplasm via interaction with XPO1. The nuclear export of these late
viral messengers is required for both the expression of late viral genes
(gag, pol and env) and packaging of genomic RNA.
As the main effector of nuclear-cytoplasmic transport in cells, XPO1
also exports cargos such as tumor suppressor and growth regulatory
proteins. Deregulation of the XPO1-mediated nuclear export can result
in uncontrolled cell growth and carcinogenesis (Kau et al., 2004;
Turner and Sullivan, 2008) and increased expression of XPO1 has
been observed in several cancers (van der Watt et al., 2009; Yao et al.,
2009; Huang et al., 2009; Noske et al., 2008). Several inhibitors
of XPO1 exist among which leptomycin B is best known (Nishi et al.,
1994; Wolff et al., 1997). Inhibition of XPO1 restores tumor suppressor
function and induces cytotoxicity in cancer cells (Lain et al., 1999; Smart
et al., 1999). Another XPO1 inhibitor CBS9106 showed anti-tumor activ-
ity in a variety of cancer cell lines and displayed tumor growth suppres-
sion in multiple myeloma xenograft (Sakakibara et al., 2011). However,
the effect of XPO1 inhibition on PEL has not been studied. Recently se-
lective inhibitors of the exportin-1 (XPO1) mediated nuclear export
(SINE) were found to have great potential against various solid and
hematological cancers in in vitro as well as in vivo models of NHL and
other hematological malignancies (Etchin et al., 2013a,b; Inoue et al.,
2013; Lapalombella et al., 2012; Tai et al., 2014; Zhang et al., 2013;
Ranganathan et al., 2012; Kojima et al., 2013). SINE are orally bioavail-
able optimized analogues of the N-azolylacrylate small-molecule inhib-
itors affecting XPO1-mediated nuclear export (Van Neck et al., 2008;
Daelemans et al., 2002). They selectively bind into the hydrophobic
cargo-binding pocket of XPO1 and interact covalently with Cys528
of XPO1 through a Michael type addition (Etchin et al., 2013b;
Lapalombella et al., 2012; Van Neck et al., 2008; Neggers et al., 2015).
The lead SINE selinexor (KPT-330) is currently in different Phase 1
and 2 clinical studies for solid and hematological malignancies and
early results show that selinexor is well tolerated with clear anti-
tumor activity.
As the majority of PEL cases occur in HIV-seropositive patients and
the use of antiretroviral therapy appears to be associated with better
prognosis, a dual anti-neoplastic and anti-retroviral effect by targeting
a common process in both diseases may be beneficial in the treatment
of PEL. In this studywe demonstrate that inhibition of XPO1 by SINE po-
tently suppresses both HIV and PEL. This combined effect may be clini-
cally relevant in HIV-infected PEL patients and provides the basis for the
use of XPO1 inhibitors as an innovative anti-PEL therapeutic approach.
2. Materials and Methods
2.1. Cell Lines and Reagents
PEL cell lines BC-1 (Cesarman et al., 1995) (ATCC), BCBL-1 (Renne
et al., 1996) and JSC-1 (Cannon et al., 2000) were cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum andgentamicin (Gibco BRL). HEK293T cells weremaintained in DMEM sup-
plemented with 10% fetal bovine serum and gentamicin (Gibco BRL).
Cell lines acquired from ATTC were thawed, enlarged and immediately
cryopreserved in multiple batches. Cells were thawed from these
batches and kept for no longer than 6 months in culture. Peripheral
blood mononuclear cells (PBMCs) were isolated by density centrifuga-
tion (Lymphoprep).
2.2. Cell Viability, Cell Cycle and Apoptosis
Cell viability was measured using either MTT assay (Pannecouque
et al., 2008) or the AlexaFluor488 Annexin V-Dead Cell Apoptosis Kit
(Life Technologies), and/or the Live–Dead Cell Viability Assay (Life
Technologies), using a FACSCanto II flow cytometer (BD Biosciences).
Cell cycle analysis was performed using the BD Cycletest PLUS (BD
Biosciences) according to the manufacturer instructions. DNA content
was determined on a FACSCanto II flow cytometer (BD Biosciences).
2.3. Immunofluorescence Staining
Cells were treated with 1 μM of compound or solvent (DMSO) for
16 h. Cells were washed in PBS and transferred into a Labtek 8-well
chambered coverglass, pretreated with 0.1% (w/v) poly-L-lysine
(Sigma). Cellswere allowed to adhere to the slides and carefullywashed
with PBS. Cells were then fixed with 4% aqueous PFA solution, washed
and permeabilized (0.1% Triton X-100 in PBS). They were then further
treated for immunofluorescence staining according to standard proce-
dures. Cell nuclei were counterstained using DAPI. Employed antibodies
were mouse monoclonal anti-p53 (DO-1) (sc-126) and, rabbit anti-p73
(H-79) (sc-7957) at 1:100 dilution (both from Santa Cruz Biotechnology)
at a 1:100 dilution, and secondary Alexa Fluor® 488 goat anti-mouse or
goat ant-rabbit antibody (A11001, A11008, resp., Molecular Probes).
Images were collected with a Leica TCS SP5 confocal microscope (Leica
Microsystems, Mannheim, Germany), employing a HCX PL APO 63×
(NA 1.2) water immersion objective.
2.4. Western Blot Analysis
Western blot was performed according to standard protocol.
Briefly, cells were seeded at 0.5 × 106 cells/ml in 24 well plates contain-
ing RPMIwith 10% FCS. Compoundswere added and incubated for 16 h,
washedwith ice-cold phosphate buffered saline (PBS) and lysed in lysis
buffer (50 mM Tris–HCl, 50 mMNaCl, 5 mMMgCl2, 0.5% Triton and 1×
Halt protease inhibitor cocktail (Thermo Scientific) for 1 h on ice
(20 × 106 cells/ml). Lysates were cleared by centrifugation and the sol-
uble supernatant was collected. Protein lysates were resolved by SDS-
PAGE and transferred to Amersham Hybond™-P membrane (GE
Healthcare). The membranes were incubated for 1 h at room tempera-
ture in blocking buffer (5% nonfat dry milk in PBS containing 0.05%
Tween 20) and subsequently for 12 h at 4 °C in blocking buffer with pri-
mary antibodies raised against PARP-1 (sc-8007, Santa Cruz Biotechnol-
ogy) caspase-3 (sc-271028, Santa Cruz Biotechnology), p53 (sc-126,
Santa Cruz Biotechnology), XPO1 (ab24189, Abcam) and α-Tubulin
(sc-5286, Santa Cruz Biotechnology). After washing, the membranes
were incubated with anti-mouse (sc-2005, Santa Cruz Biotechnology)
or anti-rabbit (ab97064, Abcam) horseradish peroxidase-conjugated
secondary antibody in blocking buffer for 20 min at room temperature.
Subsequently the membranes were washed extensively and detected
by addition of chemiluminescent substrate (Thermo Fisher Scientific).
2.5. Anti-HIV Testing
PBMCs were isolated by density centrifugation (Lymphoprep; Axis-
Shield, PoC AS, Oslo, Norway) and stimulated with 2 μg/ml phytohe-
magglutinin (PHA) (Sigma) for 3 days. Then the cells were washed
three times with PBS and viral infections were performed as described
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the presence of 25 U/ml of IL-2 for 4 days to allow virus spreading.
Subsequently, supernatant was removed, cells were washed with PBS
and incubated in the presence of varying concentrations of drugs. Su-
pernatant was collected the next day in order to assess virus production
by quantifying the virus-associated core antigen (p24) by ELISA (GE
Healthcare). Cytotoxicity was measured in parallel on mock-infected
cells using flow cytometry.2.6. Time-of-addition Experiments
Time-of-addition experiments were performed as described
(Daelemans et al., 2011). Briefly, C8166 cells were infected with HIV-1
(IIIB) at anm.o.i. of 0.5. Following a 1 h adsorption period cells were dis-
tributed in a 96-well tray at 45,000 cells/well and incubated at 37 °C.
Test compounds were added at different times (0–24 h) after infection.
HIV-1 production was determined at 31 h postinfection via a p24 ELISA.2.7. Northern Blot Analysis
mRNA was extracted using the Oligotex Direct mRNA kit (Qiagen),
treated with RNase-free DNase I (Invitrogen), and separated by agarose
electrophoresis under denaturing conditions. mRNA was blotted using
the NorthernMax-Gly system (Ambion) according to manufacturers
manual. The biotin labeled RNA probe spanning exon 7 from the
BamHI to the BglII site (nt 8475 through 9056) of the NL4-3 genome
was produced by in vitro transcription from T7 primer PCR products.2.8. CRISPR-Cas9 Genome Editing
The genome editing was performed as described in Neggers et al.
(2015). Briefly, HEK293T cells were transfected with a Cas9 expres-
sion construct, the optimized sgRNA construct (both obtained from
ToolGen-Labomics) and a 135 base oligonucleotide (IDT) for homolo-
gous recombination. The sgRNA targets the XPO1 sequence: 5′-GGATTA
TGTGAACAGAAAAGAGG-3′ and the 135 base oligonucleotide consisted
of the following sequence: 5′-GCTAAATAAGTATTATGTTGTTACAATAAA
TAATACAAATTTGTCTTATTTACAGGATCTATTAGGA TTATCAGAACAGAA
gcGcGGCAAAGATAATAAAGCTATTATTGCATCAAATATCATGTACATAGTA
GG-3′ Bold indicates the Cys528Ser missense mutation, lowercase indi-
cates additional silent mutations to prevent Cas9 mediated cleavage of
the mutated allele.2.9. Microscopy
Transfected HeLa cells were imagedwith a laser scanning SP5 confo-
calmicroscope (LeicaMicrosystems) equippedwith a DMI6000Bmicro-
scope and an AOBS, using a HCX PL APO × 63 (NA 1.2) water immersion
objective. Different fluorochromes were detected sequentially using ex-
citation lines of 405 nm (BFP), 488 nm (GFP, YFP) or 561 nm (mRFP).
Emission was detected between 410–480 nm (BFP), 493–565 nm
(GFP), 500–580 nm (YFP) and 566–670 nm (mRFP).2.10. Evaluation of NF-κB Activity
Cells were transfected using the Neon system (Life Technologies)
with plasmids expressing the firefly luciferase either driven either by
a promotor containing 6 NF-κB binding sites (NF-κB-Luc) or by the con-
trol CMV promotor (CMV-Luc) and incubated in the presence of differ-
ent concentrations of compounds. Next cells were harvested and
analyzed for luciferase expression. Signal from NF-κB-Luc reporter was
normalized according to the signal from the control CMV-Luc reporter.2.11. Mouse Xenograft Model
Female NMRI nudemice (4weeks old) were purchased from Janvier
Breeding Center (Le Genest St Isle, France) and maintained in a
temperature- andhumidity-controlled environment.Micewere injected
subcutaneouslywith 2× 107 BC-1 cells in 50%Matrigel (BD Biosciences).
Treatment per oswas started after the tumorswere established. KPT-330
(20 mg/kg) or vehicle control was administered twice a week for a total
of 4weeks. Tumor volumesweremeasuredwith a caliper and calculated
according to the formula V= (length ×width2) / 2. In order to monitor
the health of the animals, the mice were weighed once per week. All
animal studies were approved by the KU Leuven Ethics Committee
for Animal Care and Use. Statistical analysis was performed using
ANOVA.
2.12. Statistical Analyses
Data are presented as mean ± SEM. Comparisons were performed
by two-tailed paired t-test or by ANOVA followed by Bonferroni's cor-
rection, as adequate. A P value b 0.05 was considered as statistically
significant.
3. Results
3.1. Inhibition of XPO1 Suppresses the Replication of HIV in Primary Cells
KPT-185 (Fig. 1A) is a SINE compound that effectively and selectively
inhibits the XPO1-mediated nuclear export (Neggers et al., 2015). To
evaluate the effect of inhibition on HIV replication, we determined the
anti-HIV activity of KPT-185 in primary human peripheral bloodmono-
nuclear cells (PBMCs). Upon treatment of HIV-infected PBMCs for 24 h,
KPT-185 displayed potent anti-HIV activity in these primary cells (IC50:
40±14nM) (Fig. 1B). The compoundproved active against viral strains
using the CXCR4 or CCR5 chemokine co-receptor while it caused cyto-
toxic effects only at concentrations that were 850-fold higher than the
active concentration (CC50: 34 ± 13 μM) as measured by calcein AM
staining and confirmed by annexin-PI flow cytometry. Furthermore,
KPT-185 also suppressed the replication of a clinical isolate (MDR)
that was resistant to nucleoside reverse transcriptase inhibitors (NRTI)
and protease inhibitors (PI) as well as clinical virus isolates from differ-
ent subtypes of group M (Table 1). These results illustrate the broad-
spectrum anti-HIV activity of XPO1 inhibition.
3.2. KPT-185 Suppresses HIV Replication by Targeting the Nuclear Export of
Rev-dependent Viral mRNA
To ascertain that the mechanism of the observed inhibition of virus
replication by KPT-185 is caused by the inhibition of XPO1 function
we engaged in detailed mechanism of action studies. First we per-
formed a time-of-addition experiment (Daelemans et al., 2011). This
experiment is based on the fact that HIV undergoes several well-
established successive chronological processes and for almost each of
these processes well-characterized inhibitors exist. In this experiment,
in which a single replication cycle of the virus is followed, it is deter-
mined how long the addition of a drug can be postponed before it
loses its anti-HIV activity. Comparing the time-of-addition profile of an
investigational drug to that of classical anti-HIV inhibitors with known
target of action, narrows down the time frame of action and thus the
possible target of action of the investigational drug. For instance, an in-
hibitor interfering with the reverse transcription process will suppress
virus replication when added at a time point before the fulfillment of
the reverse transcription process (i.e. approximately 4–5 h post
infection), but not if added at a time point after the reverse transcription
process has already occurred (Fig. 2A). In this experiment, KPT-185
shows the same profile as the viral transcription inhibitor WP7-5, sug-
gesting that KPT-185 interferes with a process coinciding with viral
Fig. 1. Structure and anti-HIV activity of KPT-185. (A) Structure of KPT-185. (B) Activity of KPT-185 against HIV-1 CXCR4- (IIIB) and CCR5- (BaL) using virus and amultidrug resistant clin-
ical isolate (MDR) inprimary peripheral blood lymphocytes. Virus-infectedPBMCswerewashed 4 days after infection to remove virus in the supernatant andwere subsequently incubated
with different concentrations of KPT-185 for 1 day. Virus production was analyzed by monitoring the virus-associated p24 core protein in the supernatant by ELISA. Cellular toxicity was
measured in parallel using calcein AM live staining and AnnexinV-PI flow cytometry. Error bars represent standard deviations, n = 5.
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late HIV RNAs occurs co-transcriptionally (Nawroth et al., 2014).
To narrowdown themechanismbywhich KPT-185 inhibits HIV rep-
licationwe analyzed the expression levels of the different viral RNA spe-
cies. Therefore, we visualized the viral mRNA species isolated fromHIV-
1 infected PBMCs treated with KPT-185 by northern blot (Fig. 2B). A
clear reduction of the late viral mRNA species (9 kb: unspliced and
4 kb: singly spliced) that are dependent on the Rev-XPO1-mediated
transport for their expression (Malim et al., 1989b) was observed, dem-
onstrating that KPT-185 suppresses the expression of these mRNA
forms. This is in contrast to the early RNA forms (2 kb: fully spliced)
that are expressed independently of XPO1, and were even increased in
conditionswhere the late RNA formswere reduced.We assume this ob-
servation is caused by retention of the viral intron-containing RNA in
the nucleus eventually leading to degradation or splicing into fully
spliced RNA forms. Although we have used whole cell lysate and did
not separate between cytoplasmic and nuclear fraction the observed
specific reduction of intron-containing RNA species is considered to be
caused by inhibition of their nuclear export. This is in agreement with
earlier published northern blot experiments with amutant HIV-1 strain
(fB) that is defective in the Rev-XPO1-mediated nuclear RNA export. In
whole cell lysates of cells transfected with this mutant, the amount of
unspliced genomic length mRNA was also reduced while the fully
spliced 2 kb viral mRNA species augmented (Hadzopoulou-Cladaras
et al., 1989). In addition, the increase of fully spliced 2 kb viral tran-
scripts upon treatment with KPT-185 suggests that the compound
does not inhibit the transcription process as transcription is supposed
to be uniform for both the early and late viral RNA forms. Altogether
these observations suggest that KPT-185 specifically inhibits the Rev-
XPO1-mediated export of the late viral RNA species from the nucleus
to the cytoplasm.
To further support this conclusion we engineered a viral-like mRNA
that can be tagged with GFP through the bacteriophage MS2 coat pro-
tein (Shav-Tal et al., 2004) in order to visualize the RNA inside the
cell. In cells co-expressing the viral-like intron-containing mRNA (LTR-
gag-24xMS2-RRE) together with the MS2-GFP protein, individual
mRNAmolecules could be observed in the nucleus (Fig. 2C). In the pres-
ence of the viral Rev protein, which directs transport of viral intron-Table 1
Broad-spectrum anti-HIV activity of KPT-185 against clinical isolates from different
subtypes of group M.
EC50 (nM)
Strain
(subtype)
UG275
(A)
US2
(B)
ETH2220
(C)
UG270
(D)
BZ-163
(F)
BcF-Kita
(H)
BCF-Dioum
KPT-185 55.2 ±
6.6
34.8 ±
3.6
42.9 ±
8.7
38.1 ±
8.5
52.8 ±
9.2
30.3 ±
11.1
37.1 ± 9.6containing RNA to the cytoplasm through the interaction with the
XPO1 protein, the tagged viral-like RNA translocates to the cytoplasm.
Upon treatmentwith KPT-185, this RNA is trapped in the nucleus, dem-
onstrating that its nuclear export is blocked by the compound (Fig. 2C).
Altogether, these results show that indeed KPT-185 inhibits the trans-
port of intron-containing HIV RNA to the cytoplasm and traps it in the
nucleus. Correspondingly, KPT-185 inhibited the nuclear export of the
viral protein Rev (Fig. 2D). Therefore we used a Rev mutant protein
(RevM5) that is fused to GFP that predominantly confines to the
cytoplasm but it is still functional in shuttling between nucleus and
cytoplasm (Daelemans et al., 2004; Malim et al., 1989a). Knockdown
of XPO1 expression resulted in nuclear accumulation of RevM5-GFP
(Fig. 2D) demonstrating the XPO1-dependent cytoplasmic localiza-
tion of RevM5-GFP. Similarly, in KPT-185 treated cells the RevM5-
GFP relocated to the nucleus within 3 h indicating that its XPO1-
dependent export from the nucleus is inhibited (Fig. 2D, Supplemen-
tary Figure S1, and Movie S1).
3.3. KPT-185 Disrupts the Rev-XPO1 Interaction in Cells
We next analyzed the effect of KPT-185 on the Rev-XPO1 interac-
tion in cells using a fusion of Rev to the blue fluorescent protein (Rev-
BFP) and XPO1 fused to the yellow fluorescent protein (XPO1-YFP)
(Fig. 2E). In agreementwith previously published data, when expressed
separately, Rev-BFP localized in the nucleoli of the cells whereas XPO1-
YFPwas found predominantly at the nuclearmembrane aswell aswith-
in the nucleus (Costes et al., 2004; Daelemans et al., 2005). When both
proteins are co-expressed, a significant fraction of XPO1-YFP is found in
the Rev-containing nucleoli suggesting interaction between the two
proteins. Treatment of cells co-expressing Rev-BFP and XPO1-YFP
with 1 μM KPT-185 abolished this Rev-dependent XPO1-YFP nucleolar
localization indicating that KPT-185 disrupts the Rev-XPO1 interaction
inside living cells (Fig. 2E; also see Movie S2). As a control, XPO1-YFP
co-localized only very weakly with the transdominant negative
RevM10-BFP mutant (containingmutations in its NES that hampers in-
teraction with XPO1), demonstrating that the observed co-localization
with wild-type Rev-BFP is NES-specific (Supplementary Figure S2).
3.4. CRISPR-Cas9 Genome-editing Validates XPO1 as KPT-185's Target in
HIV Replication
To further prove that the observed inhibition of the viral replication
by KPT-185 is exclusively caused by inhibition of XPO1 and not by off-
target or unspecific effects, we generated a HEK293T cell-line express-
ing the resistant XPO1C528S protein. Mutating the Cys528 in the hydro-
phobic cargo-binding groove of XPO1 to a serine residue confers
resistance to KPT-185 (Neggers et al., 2015). We used CRISPR-Cas9
genome editing in combination with homology directed repair to
Fig. 2.Anti-HIVmechanism of action of KPT-185. (A) Time-of-addition experiment. C8166 cells were infectedwith HIV-1 at time 0 and inhibitors were added at different time points post
infection. Virus productionwas determined by virus associated p24 production in the supernatant at 31 h after infection. Control:mock treated, nevirapine (7.5 μM): reverse transcriptase
(RT) inhibitor; L870, 810 (1.6 μM): integrase (IN) inhibitor; WP7-5 (0.32 μM): transcription inhibitor; ritonavir (2.8 μM): protease (PR) inhibitor; KPT-185 (0.125 μM). Representative of
data for 2 independent experiments. (B) KPT-185 suppresses expression of intron-containing late viral RNA species. Northern blot analysis of the viral mRNA species (fully spliced: 2 kb;
partially spliced: 4 kb; unspliced: 9 kb) in PBMCs infectedwith HIV-1 IIIB and treatedwith different concentrations of KPT-185. (C) KPT-185 blocks the Rev-XPO1-mediated nuclear export
of intron-containing viral RNA. Top: Schematic view of the MS2-tagged Rev-dependent viral-like RNA, pLTR-p57-24xMS2-RRE. Bottom: HeLa cells were co-transfected with plasmids
encoding MS2-GFP and Rev-BFP and an RRE containing viral-like RNA construct carrying 24 MS2 recognition sites, as indicated. After overnight incubation, the sub-cellular localization
offluorescent proteinswas visualized by confocal fluorescencemicroscopy in both GFP andBFP channels. The right column shows overlays of both channels togetherwithDIC (differential
interference contrast) images. The insets show amagnification of the 10 μm× 10 μmboxed area in ‘glow’ color lookup table. Scale bar, 25 μm. (D) KPT-185 inhibits the transport of HIV-1
Rev protein. HeLa cells transfectedwith RevM5-GFP, amutant of Rev, were analyzed by confocal microscopy. RevM5-GFP is found in the cytoplasm of the cells. Inhibition of nuclear export
by siRNA knock down of XPO1 causes the RevM5-GFP protein to accumulate in the nucleus. Similarly, treatmentwith KPT-185 results in a redistribution of RevM5-GFP to the nucleus. See
also Figure S1 and Movie S1. (E) KPT-185 disrupts the XPO1-Rev interaction in living cells. HeLa cells expressing Rev-BFP and/or XPO1-YFP were analyzed by confocal fluorescence
microscopy. Rev-BFP is found in the nucleoli of the cells, while XPO1-YFP concentrates at the nuclear membrane. In cells co-expressing both Rev-BFP and XPO1-YFP, XPO1 is redistributed
to the Rev-containing nucleoli and co-localizeswith Rev-BFP. Two hours after addition of compound the co-localization ofwild-type XPO1-YFPwith Rev-BFP in the nucleoliwas disrupted.
See also Movie S2.
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HEK293T cells. HEK293T cellswere transfectedwith Cas9 endonuclease,
a 23-bp guide RNA and a 135 base single stranded oligodeoxynucleotiderepair donor template containing the TCA mutant codon to introduce
the serine at position 528 in the XPO1 gene. Single cell derived colonies
were analyzed for the mutation in their genomic DNA by Sanger
Fig. 3.KPT-185 does not inhibit viral production in CRISPR-Cas9 genome-edited cells expressing the resistant XPO1C258Smutant protein. (A) Sequencing chromatogramof genomic DNA of
the XPO1 region around the targeted cysteine codon from homozygousmutant XPO1C528S cells. Mutated codon (528 TGT➔ TCA) is indicated in bold. The sgRNA sequence of the CRISPR is
underlined and the PAM motif is given in magenta. (B) Wild-type and mutant XPO1C258S HEK293T cells were transfected with HIV-1 molecular clone NL4-3 and treated with different
concentrations of KPT-185. Virus production was analyzed by virus-associated p24 Gag protein in the supernatant. Error bars represent standard deviations, n = 3.
1107E. Boons et al. / EBioMedicine 2 (2015) 1102–1113sequencing (Fig. 3A). A homozygous mutant colony was selected for
further experiments. The mutant HEK293T-XPO1C528S cell line or wild-
type HEK293T cells were transfected with the HIV-1 molecular clone
NL4-3 and treated with different concentrations of KPT-185. Twenty-
four hours after treatment, culture supernatants were analyzed for the
presence of virus (Fig. 3B). Absolute virus production was about 3
times lower in mutant cells as compared with wild-type cells. KPT-
185 suppressed virus production from transfected wild-type HEK239T
cells, while it had no effect on virus production from the mutant
HEK293T-XPO1C528S cells. These results unambiguously demonstrate
that the anti-HIV activity of KPT-185 is exclusively caused by inhibition
of XPO1 and confirm that cysteine528 is involved in the mechanism of
action of KPT-185.
3.5. XPO1 Inhibition Induces Selective Cytotoxicity, Apoptosis and Cell Cycle
Arrest in PEL Cell Lines
KPT-185 has shown promising activity in different types of hemato-
logical cancers including NHL. Because PEL is an aggressive NHL with
very poor prognosis and typically occurs in HIV-infected individuals
we next evaluated the anti-PEL activity of KPT-185. The expression of
XPO1 was first examined in PEL cell lines BC-1, BCBL-1, and JSC-1 by
immunoblotting. XPO1 was highly overexpressed in these PEL cell
lines as compared to normal cells (Fig. 4A). Therefore, the cytotoxic ef-
fect resulting from the inhibition of the XPO1-mediated nuclear protein
export by KPT-185 was investigated in these PEL cell lines. PEL cell lines
were cultured in the presence of increasing concentrations of com-
pound for 72 h and cell viability was analyzed by MTT reduction. KPT-
185 caused significant cytotoxicity in all PEL cell lines at submicromolar
concentrations with EC50 values around 100 nM while they did not
drastically affect PBMCs at much higher concentrations (Fig. 4B). The
inhibitory effect of KPT-185 for PEL cells was confirmed by annexin V-
PI staining as early as 24 h after treatment (Fig. 4C). High levels of
annexin V staining at submicromolar concentrations of KPT-185 indi-
cate that cells undergo apoptosis within the same timeframe. This in-
duction of apoptosis in PEL was caspase-dependent as demonstratedby caspase-3 and PARP cleavage (Fig. 4D). To further examine the effect
of KPT-185 on the cell cycle of BC-1, BCBL-1 and JSC-1 cells, cell cycle
distribution was determined by DNA PI staining of cells incubated
with different concentrations of KPT-185 for 24 h (Fig. 4E). PEL cells un-
dergo cell cycle arrest in G1 upon treatment with KPT-185 while the S-
and G2/M-phase of proliferating cells decreased. Consistent with the
levels of annexin V staining, an increase in subG1 apoptotic cells is
also observed and becomes evenmore pronounced at higher compound
concentrations. These results show that KPT-185-mediated inhibition of
XPO1 induces cell cycle arrest and causes apoptosis in PEL cells.
3.6. KPT-185 Treatment Causes Nuclear Accumulation of p53 Cargo and
Affects NF-κB Activity in PEL Cells
Inhibition of XPO1 is known to result in nuclear accumulation of its
cargo proteins such as p53 and IκB (Lapalombella et al., 2012). There-
fore, we first investigated the effect of KPT-185 on p53 tumor suppres-
sor expression and nuclear accumulation. Upon treatment of BC-1,
BCBL-1 and JSC-1 cells with KPT-185we observed a significant accumu-
lation of nuclear p53 in all cell lines as demonstrated by immunofluores-
cence staining (Fig. 5A) andwestern blot (Fig. 5B). Also nuclear levels of
p73 were shown to increase upon KPT-185 treatment, further demon-
strating the nuclear accumulation of tumor suppressor cargo proteins
(Supplementary Figure S3). The augmentation in nuclear p53 levels
was accompanied by an intense p53 response as evidenced by the in-
crease in expression of the p21 target gene (Fig. 5C). In BCBL-1 cells
this response is lower than in BC-1 and JSC-1 cells, which can be ex-
plained by the p53 status of the cells; while BC-1 and JSC-1 cells are
p53 wild-type, BCBL-1 cells are heterozygous for the M246I mutation
(Petre et al., 2007).
NF-κB is constitutively active in PEL cells and plays a crucial role in
their survival (Guasparri et al., 2004; Keller et al., 2000, 2006). Because
IκB, the endogenous inhibitor of NF-κB, is also a XPO1 cargo protein we
next examined if NF-κB activity could also be affected by KPT-185 treat-
ment. Nuclear trapping of IκB by XPO1 inhibition has been demonstrat-
ed to reduce NF-κB activity (Lapalombella et al., 2012; Zhang et al.,
Fig. 4. XPO1 inhibition by KPT-185 induces selective cytotoxicity, apoptosis and cell cycle arrest in PEL cells. (A) PEL cell lines, BC-1, BCBL-1 and JSC-1, andwhole PBMC fraction from nor-
mal donors were examined for XPO1 expression by western blot. (B) Cell viability of BC-1, BCBL-1 and JSC-1 treated cells as measured by MTT-assay, as compared to treated PBMCs as
measured by annexin V-PI flow cytometry. Error bars represent standard error of mean, n ≥ 2. (C) Detection of apoptosis in BC-1, BCBL-1 and JSC-1 cells as early as 24 h after KPT-185
treatment asmeasuredby annexinV-PIflow cytometry. Error bars represent standard error ofmean, n ≥2. (D)XPO1 inhibition promotes cell death througha caspase-dependent pathway.
PEL cells were treated overnightwith KPT-185 in the absence or presence of the general caspase inhibitor Q-VD-OPH.Whole cell extractswere assessed for cleavage of PARP and caspase 3
by western blot analyses. (E) BC-1, BCBL-1 and JSC-1 cells were treated with different concentrations of KPT-185 and stained with PI (BD Cycletest Plus, BD Biosciences) for cell cycle
profiles using flow cytometric analysis. Upon treatment with KPT-185 a clear reduction of the G2/M and S populations is observed while the G0/G1 population increased as well as the
subG1 population. Error bars represent standard error of mean, n ≥ 2.
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luciferase activity driven by a promotor containing 6 NF-κB binding
sites (Fig. 5D). In untreated conditions the levels of NF-κB activity
varied among the 3 cell lines as basal activity of NF-κB was about
10 times higher in BC-1 cells when compared to BCBL-1 or JSC-1
cell lines. Treatment with KPT-185 resulted in reduction in NF-κB-driven luciferase activity. This effect was confirmed by the decrease
in the NF-κB target gene XIAP expression (Fig. 5E). However, in-
crease of nuclear IκB-α levels was only observed for BC-1 cells
(Fig. 5F). Altogether, these results demonstrate that KPT-185 can
functionally increase the levels of p53 and inactivate NF-κB activity
in PEL cells.
Fig. 5. KPT-185 increases nuclear p53 levels, decreases XPO1 protein level and affects NF-kB activity. (A) Immunostaining of p53 in PEL cells treated overnight with 1 μM KPT-185 shows
increase in nuclear p53 levels as compared to vehicle control. See also Figure S3. (B) Representative blot and densitometry of p53 expression in nuclear extracts of BC-1, BCBL-1 and JSC-1
cells after treatmentwith 0.5 or 1 μMKPT-185. Actinwasused as a loading control. Results aremeans±SEM (n=3) * P b 0.05, ** P b 0.01 or *** P b 0.001 vs. respective untreated control by
paired t-test. See also Figure S4 for control of the nuclear extracts. (C) KPT-185 enhances nuclear function of p53. Densitometry of the p53 target gene p21 expression in nuclear extracts of
PEL cells after treatmentwith 0.5 or 1 μMKPT-185 for 8 h. Actinwas used as a loading control. Results aremeans± SEM (n=2). (D) BC-1, BCBL-1 and JSC-1were transfected eitherwith a
6×NF-κB-Luc reporter plasmid or a control CMV-Luc plasmid and treatedwith 0.5 or 1 μMKPT-185. Luciferase activity wasmeasured and signal fromNF-κB-Luc reporterwas normalized
according to the signal from the control CMV-Luc reporter. Results aremeans± SEM (n= 3) * P b 0.05, ** P b 0.01 or *** P b 0.001 vs. respective untreated control by paired t-test. (E) Blot
and densitometry of XIAP expression in whole extracts of BC-1, BCBL-1 and JSC-1 cells after treatment with 0.5 or 1 μM KPT-185. Actin was used as a loading control. Results are
means ± SEM (n = 3) * P b 0.05, ** P b 0.01 or *** P b 0.001 vs. respective untreated control by paired t-test. (F) Blot and densitometry of IκB-α expression in nuclear extracts of
BC-1, BCBL-1 and JSC-1 cells after treatment with 0.5 or 1 μM KPT-185. Actin was used as a loading control. Results are means ± SEM (n = 5) * P b 0.05, ** P b 0.01 vs. respective
untreated control by paired t-test.
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To establish the in vivo activity to XPO1 inhibition against PEL, we
engrafted athymic nude mice with BC-1 cells. Mice with tumor size of
approximately 150–200 mm3 were treated with either vehicle or
XPO1 inhibitor. For these in vivo studies KPT-330 (selinexor) was
used. It is a chemical derivative of KPT-185 with improved PK and is
the clinical candidate SINE which is currently under evaluation in
multiple phase 1 and 2 studies in humans. It has been demonstrated
that both KPT-330 and KPT-185 display the same drug-target interac-
tion profile (Neggers et al., 2015). Treatment with 20 mg/kg KPT-330
only twice a week led to a significant suppression of the BC-1 PEL
growth in vivowhile it had no effect on body weight (Fig. 6). However,
after 4 weeks of treatment in some mice tumors started to grow.
Therefore, the tumors from placebo and KPT-330 treated mice were
histologicaly examined at 4 weeks post-treatment (Fig. 6C). In both
groups, tumors with a volume ≥1000 mm3 presented areas ≥25
mitosis/mm2 (range 26–74 mitosis/mm2) and b5% p53+ cells. Tumors
of a smaller size from KPT-330 treated mice presented only areas of 1
mitosis/mm2 and N10% p53+ cells.
4. Discussion
Once in advanced stage of immunedeficiency, patients infectedwith
HIV have an increased risk of cancer development. For example primary
effusion lymphoma (PEL) is a high-grade non-Hodgkin's lymphoma of
B-cell origin that is predominantly found in HIV-seropositive individ-
uals (Horenstein et al., 1997). Here we show that KPT-185, a member
of the SINE class of compounds that are highly selective inhibitors of
XPO1 (Lapalombella et al., 2012; Neggers et al., 2015) exerts a dual
anti-HIV and anti-PEL activity. KPT-185 potently suppresses HIV-1 rep-
lication in primary cells at nanomolar concentrations, which are farFig. 6.Anti-PEL activity of KPT-330 in vivo: growth curves of KPT-330 and vehicle control-treated
xenograft that received KPT-330 or vehicle treatment per os twice a week. Data were collected
measured bymeans of a digital caliper in two directions and the formulaV= (length ×width2)
had to be euthanized because of ethical reasons. (B) Bodyweight measurements of treated and
for histological examination. In both groups, tumorswith a volume ≥1000mm3presented areas
treated mice presented only areas of 1 mitosis/mm2 and N10% p53+ cells (lower panel).below concentrations at which cellular toxicity is reached, resulting in
a favorable therapeutic index (selectivity index ≈ 850). Importantly,
the dose–response curve (Fig. 1B) displays a steep slope, which is a
major determinant for inhibitory potential and in general correlates
with good clinical outcome (Shen et al., 2008). Genome editing using
CRISPR-Cas9 in combination with homology directed repair allowed
us to generate a homozygous cell line expressingmutant XPO1 contain-
ing the Cys to Ser mutation at position 528. This mutation confers resis-
tance to KPT-185 (Neggers et al., 2015). The mutant cell line supported
HIV replication indicating that the Cys residue is not essential for viral
replication. This mutant cell line allowed us to demonstrate that KPT-
185 suppresses HIV replication by directly and specifically targeting
the XPO1 mediated nuclear export and not by off target effects. Al-
though, interferingwith a host factor is anticipated to elicit cytotoxicity,
KPT-185 displays a large therapeutic window; in addition several phase
1 studies in human have revealed a tolerability profile of this class of
XPO1 inhibitors in vivo; albeit, at doses relevant to cancer growth inhi-
bition. Our data suggest that lower concentrations of SINEmay be suffi-
cient to block HIV replication and therefore may limit side effects.
Furthermore, in terms of viral resistance selection, which remains a
concern in anti-HIV therapy, it is believed that targeting a viral-host
interaction may result in a slower or no selection of escape mutants as
compared to targeting the viral enzymatic functions. This is because
host proteins essential for viral replication, cannot be influenced by
viral evolution while any adaptation in the virus that could result in
drug resistance is constrained by its interaction with the cellular co-
factor. Also, the tight RNA quality control mechanism of the cell that
does not allow intron-containing mRNAs to reach the cytoplasm will
hamper the use of escape routes for the virus to this new class of inhib-
itors. A very slow or no generation of escape mutants towards SINE
could therefore be reasonably expected. This class of drugsmight there-
fore provide benefit as second-line therapy in patients with multidrugBC-1 xenografts. (A) Tumor growthwas determined in athymic nudemice bearing a BC-1
from two independent experiments including a total of 11 mice per group. Tumors were
/ 2was used to calculate the tumor volume. Atweek 3, animals treatedwith vehicle control
vehicle control mice. (C) Tumors from placebo and KPT-330 treatedmice were processed
≥25mitosis/mm2, and b5%p53+cells (upper panel). The smaller size tumors fromKPT-330
1111E. Boons et al. / EBioMedicine 2 (2015) 1102–1113resistant virus. In addition, XPO1 inhibition displays potent anti-PEL ac-
tivity both in vitro and in vivo (Figs. 4 and 6). All PEL cell lines tested
were sensitive to SINE irrespective on whether they are transformed
with KSHV alone (BCBL-1) or with both KSHV and EBV (BC-1, JSC-1),
illustrating the broad anti-tumor potential of XPO1 inhibitors. PEL are
protected from apoptosis caused by anomalous activation of several sig-
naling pathways that promote survival (Keller et al., 2000; Uddin et al.,
2005), including deregulation of p53 and NF-κB. Reactivation of p53 by
Nutlin-3a in KSHV-transformed lymphoma cells has been described to
inducemassive induction of apoptosis (Sarek et al., 2007) and inhibition
of NF-κB down-regulates specific anti-apoptosis, signaling, and growth-
related genes and induces apoptosis (Keller et al., 2000, 2006). XPO1 in-
hibition using LMBor CBS9106 has been found to affect NF-κB activation
in multiple myeloma cells (Sakakibara et al., 2011). Our results show
that besides triggering a p53 response in PEL cells, XPO1 inhibition by
KPT-185 results also in a decrease in NF-κB activity. In BC-1 cells, this
decrease is correlated with the nuclear accumulation of IκB. IκB is an
endogenous inhibitor NF-κB and a cargo of XPO1. However, in the
other two cell lines nuclear accumulation IκB was not observed,
suggesting other mechanisms for inhibition of NF-κB in these cell
lines. This difference between the cell lines could be related to the pres-
ence of latent EBV gene expression in the cells as BCBL-1 is negative for
EBV and JSC-1 has low expression of those genes (Cannon et al., 2000).
Nevertheless, inhibition of XPO1 by KPT-185 simultaneously triggers
different molecular pathways that synergize to initiate apoptosis in all
three PEL cell lines and suppresses BC-1 xenograft growth in vivo.
Although at 4 weeks after treatment tumor progression is observed in
some treated animals. A first histological inspection of these tumors
did not reveal a difference with untreated tumors in terms of mitosis
events/mm2 and % p53+ cells, in contrast to the smaller tumors ob-
served in other treated animals. A more elaborate examination may be
required to find the basis for their progression. Note that in our experi-
mental set up animals were treated only twice a week with 20 mg/kg
suggestingmore frequent dosing or higher treatment doses or a combi-
nation of both may improve the response.
Our results are in agreement with earlier studies in acute myeloid
leukemia where p53 has been found a major determinant of XPO1-
inhibition-induced apoptosis by KPT-185 (Kojima et al., 2013). In
addition, in chronic lymphocytic leukemia, mantle cell lymphoma and
multiple myeloma XPO1 inhibition by SINE blocks NF-κB activity
(Lapalombella et al., 2012; Etchin et al., 2013a,b) and down-regulates
NF-κB target genes (Lapalombella et al., 2012) by increasing nuclear
levels of IκB. NF-κB is implicated also in survival and drug resistance
in multiple myeloma (Hideshima et al., 2007) and other tumors and
SINE compounds have demonstrated promising activity in these resis-
tant hematological malignancies. Moreover, studies in chronic lympho-
cytic leukemia and multiple myeloma demonstrated the inhibitory
activity of KPT-185 on the production of the inflammatory cytokines
such as IL-6 (Lapalombella et al., 2012), which is also important for
the persistence of PEL (Jones et al., 1999).
Several studies have revealed the tolerability profile of SINE in vivo
(Etchin et al., 2013b; Lapalombella et al., 2012; Zhang et al., 2013;
London et al., 2014). Most importantly, the clinical candidate SINE
selinexor (KPT-330) is yet in several phase 1 and 2 trials in human for
advanced malignancies (clinicaltrials.gov) and demonstrated high re-
sponse rates as single agent in trials for heavily pretreated relapsed
and refractory hematological and solid tumor malignancies (Kuruvilla
et al., 2013; Chen et al., 2014). Importantly, the demonstrated in vivo
efficacy of SINE against hematological tumors indicates that the drug
is active in host cells and/or reservoirs of HIV. Although anti-HIV activity
of SINE in animal models remains to be directly demonstrated, our
in vitro results together with the demonstrated in vivo activity of SINE
in hematological tumors provide strong evidence for in vivo anti-HIV ef-
fectiveness. Furthermore, SINE might have the potential of successfully
targeting HIV persistence. In patients treated with combination antire-
troviral therapy, infected cells can persist for a long time and are animportant obstacle for curing HIV infection. Importantly it was recently
demonstrated that in many cases these persistently infected cells ex-
pand from a single clone as a result of integration in genes involved in
controlling cell growth and division which the survival and expansion
of the infected cells (Maldarelli et al., 2014). Therefore, to successfully
target HIV persistence with the aim of realizing a potential cure, it will
be important to suppress both viral replication as well as to inhibit the
expansion of infected cells.
This study defines XPO1 inhibition as a potential treatment strategy
for PEL, especially in the setting of HIV-infected individuals. Inhibition of
XPO1 not only targets multiple signaling pathways that are deregulated
in PEL but also simultaneously inhibits the replication of HIV. Conse-
quently, one single agentwith a dual role in inhibiting both PEL progres-
sion and HIV replication represents an innovative approach and opens
interesting new opportunities for PEL therapy. This could be especially
beneficial given that antiretroviral therapy correlates with a better
prognosis for PEL (Boulanger et al., 2005; Lim et al., 2005a,b).Moreover,
when treating PEL in HIV-infected patients the risk of drug interactions
between anti-cancer agents and antiretroviral drugs exists. Small-
molecule XPO1 inhibitors thus represent a promising new class of mol-
ecules for the treatment of PEL. Our findings therefore provide a strong
rationale for using clinical XPO1 small-molecule inhibitors in combined
HIV/PEL therapy and potentially other AIDS-related malignancies and
other virus-related tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.07.041.
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